A $50 Million Investment to Boost AI Capabilities in Drug Discovery
Recursion Pharmaceuticals (NASDAQ: RXRX), a trailblazer in TechBio that is revolutionizing the field of drug discovery, has received a $50 million investment from NVIDIA (NASDAQ: NVDA). The collaboration aims to expedite the development of Recursion’s AI foundation models for biology and chemistry, leveraging NVIDIA’s cloud services for broader distribution among biotechnology companies.
Unleashing the Power of AI in Biotechnology
“Recursion and NVIDIA: Pioneering Drug Discovery with AI” defines the venture as a fusion of two leading-edge companies, combining their strength to tackle the complex issue of drug discovery. Utilizing Recursion’s vast biological and chemical dataset, which surpasses 23 petabytes and contains 3 trillion searchable gene and compound relationships, the partnership will propel the training of foundation models on NVIDIA DGX™ Cloud. These models could then be licensed for commercial use on BioNeMo, NVIDIA’s cloud service for generative AI in drug discovery.
Expanding AI Potential with NVIDIA’s Expertise
“NVIDIA’s Role in Recursion’s AI Evolution” underscores the tech giant’s crucial role in optimizing and scaling Recursion’s foundation models. NVIDIA will bring its comprehensive computing expertise and robust AI stack into play. BioNeMo, NVIDIA’s cloud service for generative AI in drug discovery, introduced earlier this year, offers tools for the swift customization and deployment of domain-specific, state-of-the-art biomolecular models at scale via cloud APIs. Recursion plans to use this software to bolster its internal pipeline as well as to aid its current and upcoming partners.
Pioneering Work in Digital Biology and Chemistry
In “Revolutionizing Medicine with Generative AI”, NVIDIA’s founder and CEO Jensen Huang applauds Recursion’s pioneering efforts in digital biology and chemistry. He notes that generative AI is an innovative tool to unearth new medicines and treatments, and looks forward to working with Recursion’s world-class team to accelerate the development of the world’s largest biomolecular generative AI models. The collaboration aims to expedite drug discovery processes for biotech and pharmaceutical companies.
Recursion Pharmaceuticals’s Democratizing Efforts in Drug Discovery
Following its recent acquisition of Valence Discovery, Recursion strives to expedite the development of new technologies within the biopharma industry. “Recursion: Democratizing Access to Large-Scale Models” illustrates the company’s commitment to making such large-scale models more accessible, aiming for maximum impact in drug discovery. With this innovative approach, Recursion continues to break new ground in the biotech and pharmaceutical landscape.
Disclosure: No position. Spotlight Growth has no relationships with any of the companies mentioned in this article and did not receive payment in any form for its creation. This is an opinion article and is not meant to be financial advise. We are not broker-dealers or investment professionals. Please conduct your own due diligence. For more information on our disclosures, please visit: https://spotlightgrowth.com/disclosures/